Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. (October 2020)

• Record Type: Journal Article
• Authors: O'Cathail, Sean M.; Smith, Thomas; Owens, Rob; Zeniou, Anthi; Tsang, Yatman; Holyoake, Daniel L.P.; Murray, Louise; Harrison, Mark; Hawkins, Maria A.
• Is Part Of: Radiotherapy and oncology. Volume 151(2020)
• Page Start: 280
• Page End: 286
• Publication Date: 2020-10
• Subjects: Colorectal -- Stereotactic -- SBRT -- Oligometastatic -- Lymph node; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2020.08.012
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: SBRT for CRC results in excellent local control rates for nodal metastases. Median PFS for NM was 19 months versus 9 months for VM. Nodal site was significant prognostic factor on multivariate analysis for PFS/OS. We hypothesise an immunoediting basis for the improved outcomes of NM. Abstract: Background: Stereotactic ablative radiotherapy (SBRT) is a radical option for oligometastatic colorectal cancer (CRC) patients, but most data relate to visceral metastases. Methods: A prospective, multi-centre database of CRC patients treated with SBRT was interrogated. Inclusion criteria were ECOG PS 0–2, ≤3 sites of disease, a disease free interval of >6 months unless synchronous liver metastases. Primary endpoints were local control (LC), progression free survival (PFS) and overall survival (OS). Results: 163 patients (172 metastases) were analysed. The median FU was 16 months (IQR 12.2–22.85). The LC at 1 year was 83.8% (CI 76.4%−91.9%) with a PFS of 55% (CI 47%−64.7%) respectively. LC at 1 year was 90% (CI 83%−99%) for nodal metastases (NM), 75% (63%−90%) for visceral metastases (VM). NM had improved median PFS (9 vs 19 months) [HR 0.6, CI 0.38–0.94, p = 0.032] and median OS (32 months vs not reached) [HR 0.28, CI 0.18–0.7, p = 0.0062] than VM, regardless of whether the NM were located inside or outside the pelvis. On multivariate analysis, NM and ECOG PS 0 were significant good prognostic factors. An exploratory analysis suggests KRAS WT is also a good prognostic factor. Conclusion: Nodal site is an important prognostic determinant of SBRT that should incorporated into patient selection. We hypothesise this may have an immunoediting basis.